Alpine Immune Sciences Inc. (NASDAQ: ALPN) stock jumped 5.99% on Friday to $12.57 against a previous-day closing price of $11.86. With 1.32 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $12.81 whereas the lowest price it dropped to was $11.88. The 52-week range on ALPN shows that it touched its highest point at $14.92 and its lowest point at $4.82 during that stretch. It currently has a 1-year price target of $18.20. Beta for the stock currently stands at 1.27.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALPN was up-trending over the past week, with a rise of 0.72%, but this was down by -5.06% over a month. Three-month performance surged to 15.32% while six-month performance rose 50.90%. The stock gained 57.72% in the past year, while it has gained 71.02% so far this year. A look at the trailing 12-month EPS for ALPN yields -1.46 with Next year EPS estimates of -1.47. For the next quarter, that number is -0.34. This implies an EPS growth rate of 12.60% for this year and -24.60% for next year.
Float and Shares Shorts:
At present, 48.05 million ALPN shares are outstanding with a float of 46.13 million shares on hand for trading. On Aug 30, 2023, short shares totaled 2.52 million, which was 5.12% higher than short shares on Jul 30, 2023. In addition to Dr. Mitchell H. Gold M.D. as the firm’s Exec. Chairman & CEO, Dr. Stanford Peng M.D., Ph.D. serves as its Pres and Head of R&D.
Institutional Ownership:
Through their ownership of 86.67% of ALPN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.65% of ALPN, in contrast to 44.77% held by mutual funds. Shares owned by individuals account for 32.29%. As the largest shareholder in ALPN with 9.54% of the stake, RA Capital Management LP holds 4,691,178 shares worth 4,691,178. A second-largest stockholder of ALPN, Great Point Partners LLC, holds 3,363,688 shares, controlling over 6.84% of the firm’s shares. Lynx1 Capital Management LP is the third largest shareholder in ALPN, holding 2,670,472 shares or 5.43% stake. With a 1.73% stake in ALPN, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 851,829 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.46% of ALPN stock, is the second-largest Mutual Fund holder. It holds 718,061 shares valued at 8.87 million. Fidelity Advisor Series VII – Bio holds 0.80% of the stake in ALPN, owning 394,000 shares worth 4.87 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, ALPN reported revenue of $5.29M and operating income of -$16.49M. The EBITDA in the recently reported quarter was -$16.03M and diluted EPS was -$0.60.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALPN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALPN analysts setting a high price target of $22.00 and a low target of $16.00, the average target price over the next 12 months is $18.20. Based on these targets, ALPN could surge 75.02% to reach the target high and rise by 27.29% to reach the target low. Reaching the average price target will result in a growth of 44.79% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded ALPN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 4,000,000 while 0 shares were sold.
